CYP3A5 and prostate cancer: Firstly, CYP3A5 has a protective effect against HCC progression by acting as a suppressor of the pathogenesis and metastasis; secondly, prometastatic signal transduction in LUAD depends on CYP3A5; and finally, CYP3A5 promotes AR nuclear translocation in prostate cancer thereby playing a crucial role in AR signaling.